The clinical-stage biopharmaceutical firm confirmed that sabirnetug missed both primary and key secondary endpoints during the mid-stage study. Management has opted to terminate all clinical development of the asset immediately. This move is intended to conserve remaining cash reserves while the Newton, Massachusetts-based company evaluates potential strategic alternatives for its future.
In section Market Quotes
Acumen Pharmaceuticals Shares Crater After Alzheimer's Drug Failure
Acumen Pharmaceuticals saw its market valuation evaporate on Friday, with shares plummeting nearly 86% to hit a record low of 30 cents. The collapse followed the company's abrupt decision to scrap its lead drug candidate, sabirnetug, after the treatment failed to meet primary efficacy goals in a Phase 2 Alzheimer's trial.
Investors reacted sharply to the news, driving the stock price down to 33 cents in recent trading. The failure of the drug represents a significant blow to the company's pipeline, forcing a pivot as leadership attempts to navigate a path forward without its primary investigational product.
Comments (0)
No comments yet. Be the first!